Curaxis Pharmaceutical (Curaxis Pharmaceutical) Total Current Assets : $0.34 Mil (As of Dec. 2011)

View and export this data going back to . Start your Free Trial

What is Curaxis Pharmaceutical Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Curaxis Pharmaceutical's total current assets for the quarter that ended in Dec. 2011 was $0.34 Mil.

Curaxis Pharmaceutical Total Current Assets Historical Data

The historical data trend for Curaxis Pharmaceutical's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curaxis Pharmaceutical Total Current Assets Chart

Curaxis Pharmaceutical Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Total Current Assets

0.78

0.31

0.34

Curaxis Pharmaceutical Semi-Annual Data
	Dec08	Dec09	Dec10	Dec11
Total Current Assets	-	0.78	0.31	0.34

Curaxis Pharmaceutical Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Curaxis Pharmaceutical's Total Current Assets for the fiscal year that ended in Dec. 2011 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.022	+	0	+	0	+	0.321
	=	0.34

Curaxis Pharmaceutical's Total Current Assets for the quarter that ended in Dec. 2011 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.022	+	0	+	0	+	0.321
	=	0.34

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Curaxis Pharmaceutical (OTCPK:CURXQ) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Curaxis Pharmaceutical's Liquidation Value for the quarter that ended in Dec. 2011 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.022	-	8.918	+	0.75 * 0	+	0.5 * 0
=	-8.90

Curaxis Pharmaceutical Total Current Assets Related Terms

Thank you for viewing the detailed overview of Curaxis Pharmaceutical's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Curaxis Pharmaceutical (Curaxis Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curaxis Pharmaceutical Corp (OTCPK:CURXQ) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.curaxispharma.com

Curaxis Pharmaceutical Corp was incorporated in Delaware on February 27, 2001. It is a specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease. The Company's therapeutic platform is based on the hypothesis that diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers. Its discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer's patients and in multiple tumors will enable it to develop significant new treatments for Alzheimer's disease and may have applications for many cancers.

Executives

Timothy R Wright	director, officer: Chief Executive Officer	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Michael W George	director	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614

Curaxis Pharmaceutical (Curaxis Pharmaceutical) Headlines

No Headlines